RxDoctor Payments Data

Srinivasan Raghavan, MD

Internal Medicine · Saint Louis, MONPI 1265444608

Payments from drug & device makers

$1,413in general payments, 2019–2025

Across 70 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$409
  • Novo Nordisk$183
  • Cook Medical LLC$181
  • Lilly USA, LLC$124
  • Amgen$101
  • GSK$55
  • plus $361 from 12 others

What the payments were for

  • Food & beverage$1,413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,413 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$1,854
Medicare patients
26
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$77,628
JardianceEmpagliflozin145$71,184
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$38,647
JanuviaSitagliptin Phosphate88$36,103
RybelsusSemaglutide44$30,434
TrulicityDulaglutide23$22,335
Nurtec OdtRimegepant Sulfate11$21,623
OzempicSemaglutide16$16,081
FarxigaDapagliflozin Propanediol27$12,974
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$12,918
MounjaroTirzepatide13$12,666
Fiasp FlextouchInsulin Aspart (Niacinamide)23$12,503
MyrbetriqMirabegron44$12,420
Spiriva RespimatTiotropium Bromide23$12,059
EntrestoSacubitril/Valsartan42$11,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat$36$100,110201 claims
PfizerEliquis, Nurtec Odt$27$99,252216 claims
Novo NordiskRybelsus, Ozempic$183$46,51560 claims
GSKTrelegy Ellipta, Anoro Ellipta$55$45,78664 claims
Lilly USA, LLCTrulicity, Mounjaro$124$35,00136 claims
AstraZenecaFarxiga$11$12,97427 claims
NovartisEntresto$26$11,72442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →